Why has GW devoted so much time and effort to make a cannabinoid pharmaceutical product?
Sativex® is a cannabinoid pharmaceutical product standardized in composition, formulation, and dose, administered by means of an appropriate delivery system, which has been, and continues to be, tested in properly controlled preclinical and clinical studies. Crude herbal cannabis in any form–including a crude extract or tincture– is none of those things. We believe that most patients and most physicians should accept only a product that meets the standards of modern medicine. Since the company’s founding in 1998, GW has consistently maintained a single objective: to develop modern medicines that satisfy international standards for quality, safety, and efficacy, while also meeting the medical needs of seriously and chronically ill patients. Moreover, GW has conducted its program exclusively in accordance with the parameters of modern medical and pharmaceutical practice. GW is entirely focused on creating cannabinoid medications that can be made available on prescription to patients 1)
